Alnylam Pharmaceuticals reported $154.47M in Selling and Administration Expenses for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Selling And Administration Expenses Change
Acadia Pharmaceuticals ACAD:US $ 96.68M 9.23M
Agios Pharmaceuticals AGIO:US $ 31.51M 13K
Alnylam Pharmaceuticals ALNY:US $ 154.47M 31.91M
Amgen AMGN:US $ 1.23B 197M
Arrowhead Research ARWR:US $ 33.86M 9.27M
Avrobio Inc AVRO:US 10.16M 1.2M
Biocryst Pharmaceuticals BCRX:US $ 34.28M 1.1M
Biomarin Pharmaceutical BMRN:US $ 194.62M 22.94M
Intercept Pharmaceuticals ICPT:US $ 50.01M 10.58M
IONIS PHARMACEUT IONS:US $ 34.13M 3.47M
Mirati Therapeutics MRTX:US $ 53.95M 10.42M
Moderna Inc MRNA:US 268M 67M
Novartis NVS:US 3.5B 486M
Ptc Therapeutics PTCT:US $ 73.27M 13.28M
Regeneron Pharmaceuticals REGN:US $ 450M 109.6M
Regulus Therapeutics RGLS:US $ 2.89M 339K
Sangamo Biosciences SGMO:US $ 14.91M 1.18M
Sarepta Therapeutics SRPT:US $ 71.84M 6.22M
Takeda 4502:JP 223.43B 7.65B
Ultragenyx Pharmaceutical RARE:US $ 67.31M 7.88M
Vertex Pharmaceuticals VRTX:US $ 215.2M 39.96M
Xencor XNCR:US $ 11.27M 102K
YTE INCY:US $ 209.58M 16.62M